Denali Therapeutics Inc.
DNLI
$25.57
$0.843.40%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/16/2026
-
MarketBeat
6/24/2026
-
Simply Wall St
6/23/2026
-
Zacks Investment Research
Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million
6/22/2026
-
Simply Wall St
6/19/2026
-
Zacks Investment Research
6/18/2026
-
TipRanks
6/18/2026
-
TipRanks: TheFly
6/18/2026
-
Globe Newswire
6/16/2026
-
Tickeron - Stocks
6/13/2026
-
Simply Wall St
6/12/2026
-
Simply Wall St
6/11/2026
-
Insider Monkey
6/10/2026
-
The Cerbat Gem
6/10/2026
-
Tickeron - Stocks
6/7/2026
-
Tickeron - Stocks
6/6/2026
-
The Cerbat Gem
6/5/2026
-
SeekingAlpha
6/5/2026
-
Seeking Alpha: Transcripts
6/4/2026
-
Tickeron - Stocks
6/3/2026
-
Tickeron - Stocks
6/1/2026
-
Yahoo! Finance: News
6/1/2026
-
Simply Wall St
5/30/2026
-
Insider Monkey
5/30/2026
-
The Cerbat Gem
5/29/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 7, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 866 8547
Address
161 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib...
more